A Phase I Study to Assess the Effect of a CYP3A Inducer (Rifampin) on the Pharmacokinetics of ABT-263 (Navitoclax).

Trial Profile

A Phase I Study to Assess the Effect of a CYP3A Inducer (Rifampin) on the Pharmacokinetics of ABT-263 (Navitoclax).

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2014

At a glance

  • Drugs Navitoclax (Primary) ; Rifampicin
  • Indications Bacterial infections; Cancer; Haematological malignancies
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Dec 2010 Planned End Date changed from 1 Dec 2010 to 1 Apr 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top